Search - tctmd.com

Displaying 61 - 80 of 1782

Sort: Relevancy | Date

Presentation TCT 2016

Von Willebrand Factor Multimers During TAVR: Implications for Treatment of Para-Valvular Regurgitation

Presenter: Neil E. Moat, John G. Webb, Eric Van Belle

October 31, 2016

Presentation TCT 2016

Israel Responds: How Would I Treat?

Presenter: Ariel Finkelstein, Ugo Limbruno, Haim Danenberg

October 31, 2016

Presentation TCT 2016

Italy Presents: Case 4 Introduction A Complication of Primary PCI during STEMI

Presenter: Ariel Finkelstein, Ugo Limbruno, Giovanni Esposito

October 31, 2016

Presentation TCT 2016

A Practical Algorithm for Managing Para-Valvular Regurgitation After TAVR

Presenter: Neil E. Moat, John G. Webb, Scott Lim

October 31, 2016

Presentation TCT 2016

Complications 1. Para-Valvular Regurgitation: Should Mild Para-Valvular Regurgitation After TAVR Be Treated?

Presenter: Neil E. Moat, John G. Webb, Jeffrey J. Popma

October 31, 2016

Presentation TCT 2016

Complications of Structural Heart Disease Intervention

Presenter: George S. Hanzel, Mauricio G. Cohen

October 31, 2016

Presentation TCT 2016

Case #2: A TAVR Complication to Learn From

Presenter: Antonio Colombo, Jeffrey W. Moses, Augusto D. Pichard

October 31, 2016

Presentation TCT 2016

Israel Responds: How Would I Treat?

Presenter: Ariel Finkelstein, Ugo Limbruno, Haim Danenberg

October 31, 2016

Presentation TCT 2016

Updates on New Adjunctive Pharmacotherapy Clinical Trials for TAVR

Presenter: Raj Makkar, Lars Sondergaard, Davide Capodanno

October 31, 2016

News Conference News TCT 2016

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Yael L. Maxwell

October 31, 2016

Presentation TCT 2016

Complications That Can Occur After Transcatheter Mitral Valve Replacement

Presenter: Michael J. Mack, Ralph Stephan von Bardeleben, Neil E. Moat

October 31, 2016

Presentation TCT 2016

Italy Responds: How Would I Treat?

Presenter: Ariel Finkelstein, Ugo Limbruno, Alessio G La Manna

October 31, 2016

Presentation TCT 2016

Controversy 5. Adjunctive Pharmacotherapy for TAVR: Real World Usage Patterns of Antiplatelet and Antithrombotic Agents

Presenter: Raj Makkar, Lars Sondergaard, Luis Nombela-Franco

October 31, 2016

News Conference News TCT 2016

Cancer Patients Face Increased Risk of Acute MI, More PCI Complications, Higher Mortality, and Soaring Costs

Michael H. Wilson

October 31, 2016

Presentation TCT 2016

Israel Presents: Case 3 Introduction - A Complication of an Antegrade CTO Recanalization

Presenter: Ariel Finkelstein, Ugo Limbruno, Yaron Almagor

October 31, 2016

Presentation TCT 2016

Case #1: A TAVR Complication to Learn From

Presenter: Antonio Colombo, Jeffrey W. Moses, Samir R. Kapadia

October 31, 2016

Presentation TCT 2016

Flash Debate: Counterpoint In Lower Risk Patients, A Thoughtful Hybrid Strategy Is Preferred!

Presenter: Raj Makkar, Lars Sondergaard, Stephen J.D. Brecker

October 31, 2016

Presentation TCT 2016

Complications of Coronary and Peripheral Vascular Intervention

Presenter: Sahil A. Parikh, Ehrin J. Armstrong

October 31, 2016

Presentation TCT 2016

Flash Debate: Point In Lower Risk Patients, the Minimalist Strategy Should Be the Default Approach!

Presenter: Raj Makkar, Lars Sondergaard, Antonio Colombo

October 31, 2016

Presentation TCT 2016

Controversy 4. Will the Minimalist Strategy Dominate TAVR in the Future: Supportive Clinical and Economic Data

Presenter: Raj Makkar, Lars Sondergaard, Ganesh Manoharan

October 31, 2016

Advertisement

Von Willebrand Factor Multimers During TAVR: Implications for Treatment of Para-Valvular Regurgitation

Israel Responds: How Would I Treat?

Italy Presents: Case 4 Introduction A Complication of Primary PCI during STEMI

A Practical Algorithm for Managing Para-Valvular Regurgitation After TAVR

Complications 1. Para-Valvular Regurgitation: Should Mild Para-Valvular Regurgitation After TAVR Be Treated?

Complications of Structural Heart Disease Intervention

Case #2: A TAVR Complication to Learn From

Israel Responds: How Would I Treat?

Updates on New Adjunctive Pharmacotherapy Clinical Trials for TAVR

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Complications That Can Occur After Transcatheter Mitral Valve Replacement

Italy Responds: How Would I Treat?

Controversy 5. Adjunctive Pharmacotherapy for TAVR: Real World Usage Patterns of Antiplatelet and Antithrombotic Agents

Cancer Patients Face Increased Risk of Acute MI, More PCI Complications, Higher Mortality, and Soaring Costs

Israel Presents: Case 3 Introduction - A Complication of an Antegrade CTO Recanalization

Case #1: A TAVR Complication to Learn From

Flash Debate: Counterpoint In Lower Risk Patients, A Thoughtful Hybrid Strategy Is Preferred!

Complications of Coronary and Peripheral Vascular Intervention

Flash Debate: Point In Lower Risk Patients, the Minimalist Strategy Should Be the Default Approach!

Controversy 4. Will the Minimalist Strategy Dominate TAVR in the Future: Supportive Clinical and Economic Data

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content